Antidepressant Drugs

Correct Answer

A — Multimodal serotonergic antidepressants

Rationale

Vortioxetine is classified as a multimodal serotonergic antidepressant, distinguishing it from conventional selective serotonin reuptake inhibitors that act solely on the serotonin reuptake transporter. In addition to blocking the serotonin reuptake transporter, vortioxetine has direct agonist, partial agonist, and antagonist activity at multiple serotonin receptor subtypes. Selective serotonin reuptake inhibitors include fluoxetine and sertraline, which act only at the transporter without direct receptor activity. Serotonin antagonist and reuptake inhibitors include trazodone and nefazodone, which combine serotonin transporter blockade with serotonin-2A receptor antagonism. Noradrenergic and specific serotonergic antidepressants is the class to which mirtazapine belongs.

Correct Answer

D — Serotonin antagonist and reuptake inhibitors

Rationale

Trazodone is classified as a serotonin antagonist and reuptake inhibitor, a class that combines serotonin reuptake transporter blockade with serotonin-2A receptor antagonism. Nefazodone shares this class label and mechanism. Selective serotonin reuptake inhibitors act solely at the serotonin reuptake transporter without direct receptor antagonism. Serotonin-norepinephrine reuptake inhibitors block both the serotonin and norepinephrine transporters. Multimodal serotonergic antidepressants describes vortioxetine, which combines transporter blockade with direct activity at multiple serotonin receptor subtypes.

Correct Answer

B — Nefazodone

Rationale

Nefazodone carries a Food and Drug Administration black-box warning for life-threatening hepatic failure, including fulminant hepatic failure and fatal cases identified through post-marketing surveillance. The branded formulation (Serzone) was withdrawn from the United States market in 2004 because of this hepatotoxicity risk; generic nefazodone technically remains available but is rarely prescribed and is limited to patients with refractory depression who have exhausted safer alternatives. Trazodone shares nefazodone's pharmacological class but does not carry the hepatotoxicity classification. Vortioxetine and vilazodone do not carry hepatotoxicity black-box warnings.

Correct Answer

C — Agomelatine

Rationale

Agomelatine is approved in Europe and Australia but has not received Food and Drug Administration approval in the United States. Clinicians may encounter it in patients transferring care from European or Australian healthcare settings, making recognition of its regulatory status and prescribing constraints clinically relevant even in the United States. Vortioxetine, vilazodone, and trazodone are all Food and Drug Administration-approved antidepressants available in the United States. Agomelatine's lack of Food and Drug Administration approval relates to the agency's requirements for hepatotoxicity monitoring data and questions about its efficacy evidence base at the time of review.

Correct Answer

A — Vilazodone

Rationale

Vilazodone must be taken with food at every dose. Its bioavailability is approximately 72 percent when taken with food but falls to approximately 47 percent in the fasted state — a reduction of nearly one-third that is large enough to compromise drug exposure and potentially result in apparent treatment failure despite a correctly written prescription. Explicit counseling about this food requirement at the time of prescribing is mandatory. Vortioxetine, trazodone, and agomelatine do not have a clinically significant food dependency of this magnitude. Agomelatine must be taken at bedtime to align with the normal melatonin window, but this is a timing requirement related to its mechanism, not a food-dependency requirement for bioavailability.

Correct Answer

D — Vortioxetine

Rationale

Vortioxetine is metabolized primarily by cytochrome P450 2D6, classifying it as a cytochrome P450 2D6 substrate. When potent cytochrome P450 2D6 inhibitors — such as bupropion, fluoxetine, or paroxetine — are co-administered, vortioxetine plasma concentrations rise substantially, and a dose reduction of vortioxetine is required. This is the clinically important direction of the interaction: the inhibitor raises vortioxetine exposure. Agomelatine is metabolized primarily by cytochrome P450 1A2, not cytochrome P450 2D6. Trazodone's metabolism involves multiple cytochrome P450 enzymes but cytochrome P450 2D6 substrate status requiring clinical dose adjustment is not its defining classification. Vilazodone is not classified as a cytochrome P450 2D6 substrate with a mandatory dose adjustment requirement.

Correct Answer

B — Blockade of serotonin-3 and serotonin-7 receptors on inhibitory interneurons disinhibits norepinephrine, dopamine, and acetylcholine release in prefrontal and hippocampal circuits

Rationale

Vortioxetine's multimodal receptor profile extends beyond serotonin reuptake transporter blockade to include antagonism at serotonin-3 and serotonin-7 receptors located on inhibitory interneurons. When these receptors are blocked, the inhibitory tone that serotonin normally exerts on interneurons is removed, disinhibiting the release of norepinephrine, dopamine, and acetylcholine in prefrontal cortex and hippocampus — circuits central to attention, processing speed, and executive function. Clinical trial data support improvements in these cognitive domains with vortioxetine, appearing at least partially independent of mood improvement. Alpha-2 antagonism describes mirtazapine's mechanism, not vortioxetine's. Histamine H1 antagonism produces sedation rather than cognitive enhancement. Serotonin-1A agonism is part of vortioxetine's receptor profile but neurogenesis is not the proposed mechanism for its acute cognitive effects.

Correct Answer

C — Bioavailability drops from approximately 72% with food to approximately 47% in the fasted state, a reduction large enough to compromise drug exposure and potentially produce apparent treatment failure

Rationale

Vilazodone bioavailability is approximately 72 percent when taken with food but falls to approximately 47 percent in the fasted state — a reduction of nearly one-third. This magnitude of reduction is clinically consequential: a patient who consistently takes vilazodone without food may receive substantially less drug exposure than the prescribed dose delivers under fed conditions, potentially explaining apparent treatment failure despite an adequately dosed and correctly written prescription. Explicit counseling about this mandatory food requirement at every dose is essential at the time of prescribing and at follow-up visits. The food dependency works in the direction of food improving absorption, not reducing it — vilazodone must be taken with food, not on an empty stomach.

Correct Answer

A — At the low doses used for insomnia (50 to 150 mg), sedation from histamine H1, alpha-1, and serotonin-2A receptor blockade predominates; antidepressant doses of 300 to 600 mg produce tolerability-limiting adverse effects

Rationale

Trazodone has a dose-dependent pharmacological profile. At low doses of 50 to 150 mg taken at bedtime, its most clinically prominent effects are sedation — from histamine H1 and alpha-1 adrenergic receptor blockade — and promotion of slow-wave sleep from serotonin-2A antagonism. At these hypnotic doses, serotonin transporter inhibition contributes minimally to net serotonergic enhancement. To produce meaningful antidepressant effect through serotonin transporter blockade, doses of 300 to 600 mg per day are required. However, at these higher doses, daytime sedation and orthostatic hypotension become dose-limiting for many patients. In current practice, trazodone's hypnotic role has become its primary application, often added to a selective serotonin reuptake inhibitor or serotonin-norepinephrine reuptake inhibitor for residual insomnia. Trazodone does have serotonin transporter activity and does not produce physical dependence.

Correct Answer

D — Priapism, caused by alpha-1 adrenergic receptor blockade in penile vasculature impairing adrenergically mediated detumescence

Rationale

Trazodone causes priapism — a prolonged, painful erection unrelated to sexual arousal — in approximately 1 in 6,000 male patients. Normal penile detumescence (the return to flaccidity after erection) is mediated by norepinephrine acting at alpha-1 adrenergic receptors in the smooth muscle of penile vasculature, causing vasoconstriction that reduces inflow and promotes outflow. Trazodone's alpha-1 blockade impairs this adrenergic detumescence mechanism, allowing erection to persist. Priapism is a medical emergency: if sustained beyond four to six hours without treatment, ischemia causes permanent damage to erectile tissue and irreversible erectile dysfunction. Male patients starting trazodone must be explicitly warned before the first dose to seek emergency care immediately if erection persists beyond two to four hours. The other options describe different mechanisms and different adverse effects that are not the trazodone-specific serious adverse effect requiring pre-treatment counseling.

Correct Answer

B — Nefazodone is a potent cytochrome P450 3A4 inhibitor; simvastatin and lovastatin depend on cytochrome P450 3A4 for clearance, so nefazodone raises statin plasma concentrations to levels that increase rhabdomyolysis risk

Rationale

Nefazodone is a potent inhibitor of cytochrome P450 3A4, the enzyme responsible for the primary metabolism of simvastatin and lovastatin. By blocking cytochrome P450 3A4, nefazodone substantially reduces the clearance of these statins, raising their plasma concentrations to levels that produce a dramatically elevated risk of myopathy and rhabdomyolysis — a potentially life-threatening muscle breakdown syndrome that can cause acute kidney injury. The combination is contraindicated. This interaction also applies to other cytochrome P450 3A4-dependent drugs including triazolam, alprazolam, and pimozide. Nefazodone inhibits cytochrome P450 3A4; it does not induce it. The mechanism is pharmacokinetic and enzyme-specific, not related to receptor blockade effects on hepatic cytochrome P450 expression.

Correct Answer

C — Melatonin MT1 and MT2 receptor agonism synchronizes circadian rhythms; serotonin-2C receptor antagonism disinhibits dopamine and norepinephrine release in the prefrontal cortex

Rationale

Agomelatine produces its antidepressant and circadian effects through two complementary receptor mechanisms. As an agonist at melatonin MT1 and MT2 receptors in the suprachiasmatic nucleus — the brain's master circadian clock — it reinforces the endogenous melatonin signal and directly addresses the sleep-wake cycle disruption that is a core feature of depression. As an antagonist at serotonin-2C receptors in the prefrontal cortex, it removes the inhibitory tone that serotonin normally exerts on noradrenergic and dopaminergic neurons, increasing norepinephrine and dopamine release in frontal circuits through a mechanism entirely separate from any transporter. Because agomelatine has no transporter activity, it produces none of the class effects driven by serotonin reuptake transporter blockade: no sexual dysfunction, no gastrointestinal adverse effects, and no discontinuation syndrome. Alpha-2 antagonism describes mirtazapine. Serotonin-1A agonism is part of vilazodone's mechanism. Dopamine D2 partial agonism describes aripiprazole.

Correct Answer

A — Fluvoxamine is contraindicated because it is a potent cytochrome P450 1A2 inhibitor; since agomelatine is metabolized primarily by cytochrome P450 1A2, fluvoxamine markedly increases agomelatine plasma exposure

Rationale

Agomelatine is metabolized primarily by cytochrome P450 1A2. Fluvoxamine is the most potent cytochrome P450 1A2 inhibitor among the selective serotonin reuptake inhibitors and, when co-administered with agomelatine, markedly increases agomelatine plasma concentrations. This elevated exposure raises the risk of agomelatine's hepatotoxic adverse effects and other dose-related toxicities. The combination is therefore contraindicated. Ciprofloxacin is another potent cytochrome P450 1A2 inhibitor and carries the same contraindication. Fluoxetine and paroxetine are cytochrome P450 2D6 inhibitors, not cytochrome P450 1A2 inhibitors — agomelatine is not their metabolic substrate. The interaction with venlafaxine described is not a recognized pharmacokinetic or pharmacodynamic contraindication for agomelatine.

Correct Answer

D — Vortioxetine's multimodal receptor profile — including serotonin-1A agonism and activity at multiple serotonin receptor subtypes — appears to attenuate serotonin-mediated sexual dysfunction, with prospective trial rates near placebo

Rationale

Vortioxetine shares serotonin reuptake transporter blockade with conventional selective serotonin reuptake inhibitors, yet its sexual dysfunction rates in prospective clinical trials are near placebo — substantially below the rates seen with sertraline, fluoxetine, and paroxetine. The proposed explanation is its multimodal receptor profile: vortioxetine's serotonin-1A agonism and its antagonism at serotonin-3 and serotonin-7 receptors modulate the serotonergic environment in ways that appear to attenuate the downstream serotonin-mediated effects on sexual function that occur with pure transporter blockade. This favorable profile is a clinically relevant distinction and makes vortioxetine a reasonable alternative for patients who experienced sexual dysfunction on a selective serotonin reuptake inhibitor but were otherwise tolerating their antidepressant well. Vortioxetine is a cytochrome P450 2D6 substrate, not an inhibitor, and its half-life is not the mechanistic basis for its favorable sexual dysfunction profile.

Correct Answer

C — Nefazodone carries a black-box warning for idiosyncratic hepatotoxicity, including fulminant hepatic failure and fatal cases identified through post-marketing surveillance

Rationale

Nefazodone's branded formulation (Serzone) was withdrawn from the United States market in 2004 because post-marketing surveillance identified a risk of severe idiosyncratic hepatotoxicity — estimated at approximately 1 in 250,000 to 1 in 300,000 patient-years — including cases of fulminant hepatic failure and death. The hepatotoxicity is idiosyncratic rather than dose-dependent: it cannot be predicted from dose or plasma levels and occurs in susceptible individuals for reasons that are not fully understood. Liver function monitoring at baseline and periodically during treatment is mandatory, and rising liver enzymes as seen here warrant immediate discontinuation. Generic nefazodone technically remains available in the United States with a black-box warning, but prescribing is now rare and confined to patients with refractory depression who have exhausted safer alternatives and who are informed of the risk. Nefazodone's cytochrome P450 3A4 inhibition is a separate pharmacokinetic concern unrelated to the hepatotoxicity mechanism.

Correct Answer

B — Alpha-1 adrenergic receptor blockade in penile vasculature impairs the norepinephrine-mediated detumescence mechanism that normally terminates erection

Rationale

Normal penile detumescence depends on norepinephrine acting at alpha-1 adrenergic receptors in the smooth muscle of penile vasculature to produce vasoconstriction and reduce penile blood inflow. Trazodone blocks these alpha-1 receptors, impairing this mechanism and allowing erection to persist as priapism. Priapism occurs in approximately 1 in 6,000 male patients taking trazodone and is a medical emergency: sustained high-pressure ischemic priapism beyond four to six hours causes irreversible damage to erectile tissue and permanent erectile dysfunction. Aspiration and intracavernosal phenylephrine — an alpha-1 agonist — are the treatments for this condition. Male patients must be explicitly warned before the first trazodone dose to seek emergency care immediately if erection persists beyond two to four hours. The other mechanisms listed do not account for the adrenergic basis of priapism in this context.

Correct Answer

A — Melatonin MT1 and MT2 receptor agonism synchronizes disrupted circadian rhythms; serotonin-2C receptor antagonism disinhibits dopamine and norepinephrine release in prefrontal circuits

Rationale

Agomelatine produces antidepressant and circadian-resynchronizing effects through two complementary mechanisms that are entirely distinct from monoamine reuptake transporter blockade. First, it acts as an agonist at melatonin MT1 and MT2 receptors in the suprachiasmatic nucleus — the brain's master circadian clock — reinforcing the endogenous melatonin signal and directly addressing the sleep-wake cycle disruption that is both a prominent symptom and a pathophysiological feature of major depressive disorder. Second, it antagonizes serotonin-2C receptors in the prefrontal cortex, removing the inhibitory tone that serotonin normally exerts on noradrenergic and dopaminergic neurons and increasing norepinephrine and dopamine output in frontal circuits. Because neither mechanism involves the serotonin reuptake transporter, agomelatine produces no sexual dysfunction, no nausea, and no discontinuation syndrome. Serotonin-1A agonism describes vilazodone. Alpha-2 antagonism describes mirtazapine. Monoamine oxidase B inhibition describes selegiline at low oral doses.

Correct Answer

D — Vilazodone bioavailability falls from approximately 72% with food to approximately 47% in the fasted state; consistently taking it without food produces drug exposure substantially below the level delivered under fed conditions

Rationale

Vilazodone has a mandatory food requirement because its bioavailability drops from approximately 72 percent with food to approximately 47 percent in the fasted state — a reduction of nearly one-third. A patient who consistently takes vilazodone without food receives substantially less drug exposure than the prescribed dose provides under fed conditions, which can easily explain apparent treatment failure at a dose and duration that would otherwise be considered adequate. This patient is effectively under-dosing herself through her administration habit. The clinical response is to counsel her to take vilazodone with food at every dose and reassess at four to six weeks. Vilazodone's food dependency is among the most clinically consequential absorption interactions for any commonly prescribed antidepressant. Exercise-induced changes in first-pass metabolism, timing of serotonin-1A adaptation cycles, and water-dilution of gastric acid are not recognized mechanisms for vilazodone treatment failure.